References

<h1 data-label="references" class="ltx_title_section">References</h1><div>1. Furlan I, Batz C, Flotho C, et al.
Intriguing
response to azacitidine in a patient with juvenile myelomonocytic
leukemia and monosomy7. Blood 2009; 113(12): 2867-2868. doi:
10.1182/blood-2008-12-195693.</div><div>2. Niemeyer CM, Loh ML, Cseh A, et al. Criteria for evaluating response
and outcome in clinical trials for children with juvenile myelomonocytic
leukemia. Haematologica 2015; 100(1): 17-22. doi:
10.3324/haematol.2014.109892.</div><div>3. Cseh A, Niemeyer CM, Yoshimi A, et al.
Bridging
to transplant with azacitidine in juvenile myelomonocytic leukemia: a
retrospective analysis of the EWOG-MDS study group. Blood 2015; 123(14):
2311-3. doi: 10.1182/blood-2015-01-619734.</div><div>4. Hashmi SK, Punia JN, Marcogliese AN, et al. Pediatr Blood Cancer
2019; 66(10): e27905 doi: 10.1002/pbc.27905.</div><div>5. Stieglitz E, Mazor T, Olshen AB, et al.
Genome-wide
DNA methylation is predictive of outcome in juvenile myelomonocytic
leukemia. Nat commun 2017; 8(1): 2127. doi: 10.1038/s41467-017-02178-9.</div><div>6. Murakami N, Okuno Y, Yoshida K, et al. Integrated molecular profiling
of juvenile myelomonocytic leukemia. Blood. 2018; 131(14): 1576-1586.
doi: 10.1182/blood-2017-07-798157.</div>